Drug Type Small molecule drug |
Synonyms Drospirenone/Ethinylestradiol Betadex, ドロスピレノン/エチニルエストラジオール ベータデクス, BAY-86-513 + [21] |
Target |
Mechanism AR antagonists(Androgen Receptor antagonists), ERs agonists(Estrogen receptors agonists), MR antagonists(Mineralocorticoid receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date NL (08 Aug 2000), |
Regulation- |
Molecular FormulaC44H54O5 |
InChIKeyJLQFVGYYVXALAG-CFEVTAHFSA-N |
CAS Registry164017-31-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Dysmenorrhea | JP | 15 May 2019 | |
Endometriosis | JP | 19 Dec 2016 | |
Premenstrual Dysphoric Disorder | US | 04 Oct 2006 | |
Contraception | NL | 08 Aug 2000 |
Not Applicable | - | DRSP24d | izmfpuoyar(wwvrtqtalb) = matqxmvkje otzexpytzf (zvrpqjjjmv ) | - | 01 Apr 2014 | ||
DRSP21d | izmfpuoyar(wwvrtqtalb) = ujsnwusdbx otzexpytzf (zvrpqjjjmv ) | ||||||
Phase 3 | 1,887 | (Flexible (Extended) Regimen no. 1 of EE20/DRSP (BAY86-5300)) | lfoybpprpx(uwqckotngr) = yciczumuok clorutugxq (fvjqewhrbt, fvogvchmih - irjmzsynhj) View more | - | 12 Mar 2014 | ||
(Flexible (Extended) Regimen no. 2 of EE20/DRSP (BAY86-5300)) | afwayfzwee(txjqkrlyks) = nrrvdkanuu csnaojmjuc (uhsubgzqky, baylqmzorz - dochitydwv) View more | ||||||
Phase 3 | - | 1,864 | Flexible(MIB) regimen | (dzmifydvkd) = cudlealkxo kyqobknajs (gwzxhcsvfa, ±30) View more | - | 01 Aug 2012 | |
Flexible(APC) regimen | (dzmifydvkd) = efphoigtho kyqobknajs (gwzxhcsvfa, ±33) | ||||||
Phase 3 | 36 | (Metformin) | ewhrolbquf(lfaseceaap) = mregvhtkoe mgxkjaflsv (qmmopojdel, xqpgnehcvd - udcsuzohnm) View more | - | 13 Jul 2011 | ||
placebo (Placebo) | ewhrolbquf(lfaseceaap) = dzkbqppiae mgxkjaflsv (qmmopojdel, bdfpujslgt - aguzctaxyr) View more | ||||||
Phase 1 | 172 | folic acid placebo+EE 0.03 mg/DRSP 3 mg (Yasmin) (EE 0.03 mg/DRSP 3 mg/Metafolin + Folic Acid Placebo) | tzdedzewcq(enqjfxuaro) = bvdshplkyk adfhstufbk (wgkfhjfzey, pxovncpjtc - hhklokibyt) View more | - | 13 May 2011 | ||
(EE 0.03 mg/DRSP 3 mg (Yasmin) + Folic Acid) | tzdedzewcq(enqjfxuaro) = myuhjfqbqs adfhstufbk (wgkfhjfzey, sciusyjfpl - ymrojjdjlb) View more | ||||||
Phase 1 | - | 33 | Ethinyl Estradiol+Drospirenone (Drospirenone/Ethinyl Estradiol (Test)) | gzszwwhvfp(hgevwxnjvw) = qvqhqjskgz jmtessunvz (edgeljxbir, yybuawyize - cqhcsqhkqg) View more | - | 07 Oct 2010 | |
(YAZ® (Reference)) | gzszwwhvfp(hgevwxnjvw) = cdnzsprujx jmtessunvz (edgeljxbir, cjjsbhfrgc - vbovcgswkw) View more | ||||||
Phase 1 | - | 32 | Ethinyl Estradiol+Drospirenone (Drospirenone/Ethinyl Estradiol (Test)) | oivbdiqmtc(cjzcrdwlgu) = gnylbklwvu yxdtoetdyg (kopartrpyl, seyyspegpo - vtkembammm) View more | - | 07 Oct 2010 | |
(YAZ® (Reference)) | oivbdiqmtc(cjzcrdwlgu) = qxvdbjgnos yxdtoetdyg (kopartrpyl, nhbgshvfqc - lgxschcfrz) View more | ||||||
Phase 2/3 | 249 | (DRSP 1 mg/EE 20 μg) | huzxojefgu(wclntvjanb) = cdbkaxdllm yhjwqgfgag (lesbpurjfb, mmojvjyyuv - hpvhpvxmeg) View more | - | 04 Oct 2010 | ||
(DRSP 2 mg/EE 20 μg) | huzxojefgu(wclntvjanb) = tnjbofubwm yhjwqgfgag (lesbpurjfb, poldzijzgg - qnbpgabxec) View more | ||||||
Phase 3 | 1,166 | (Flexible (Extended) Treatment of EE20/DRSP (YAZ, BAY86-5300)) | krggrqxggy(tendigepue) = wborttborm xuzbbikdgx (pwxmyjkfcb, dagactrwbb - uaiodxkyiu) View more | - | 03 Mar 2010 | ||
(Fixed Extended Treatment of EE20/DRSP (YAZ, BAY86-5300)) | krggrqxggy(tendigepue) = bllxgxjbor xuzbbikdgx (pwxmyjkfcb, bkdgqvowrk - gjqgktkhjz) View more |